GÖTEBORG, Sweden--(BUSINESS WIRE)--Regulatory News:
Vitrolife AB (STO:VITR) has terminated its market maker agreement with Remium due to the increased share trading. The agreement will cease on 2014-11-21. No new market maker has been appointed.
Gothenburg, August 22, 2014
VITROLIFE AB (publ)
Thomas Axelsson, CEO
Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on August 22, 2014 at 2:00 p.m.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
Vitrolife (http://www.vitrolife.com/en/Corporate/) is an international medical device Group. Vitrolife Fertility (http://www.vitrolife.com/en/Fertility/) product area develops, produces and markets medical devices for assisted reproduction. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes
Vitrolife (http://www.vitrolife.com/en/Corporate/) has approximately 240 employees and the company's products are sold in almost 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in USA, Australia, France, Italy, United Kingdom, China, Japan, Hungary and Denmark. The Vitrolife share (http://www.vitrolife.com/en/Corporate/Financial/The-share1/) is listed on NASDAQ OMX Stockholm (http://www.nasdaqomxnordic.com/aktier/shareinformation?Instrument=SSE13469), Small Cap.
This information was brought to you by Cision http://news.cision.com